Komori
Soiken Holdings (2385) · RiskRestated

Dependence on the Representative Director and President for Management and Business Operations

First written in FY2016. 15 of 20 entries say "Restated". Latest entry: FY2026.

20entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2018-Q2RestatedFY2019-Q1 – FY2024-Q2ReframedFY2024 – 2026-08-182016: 12017: 020172018: 320182019: 320192020: 320202021: 220212022: 020222023: 420232024: 220242025: 020252026: 22026
Same theme, other companies
Dependence on key executivesA theme 560 companies write about · 560 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 10 of 77 companies on the "Worse" side.

116 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 560 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「Tsunoda Masao (角田 真佐夫), the Company's Representative Director and President, joined the Group after working at a biotech company engaged in the sale of medical devices and pharmaceuticals. He launched the healthcare support business, also served as head of the functional-materials development business, which conducts research and development on functional materials covered by numerous patents, and became Representative Director and President in September 2024.」

    The risk of dependence on Tsunoda Masao (角田 真佐夫), the Representative Director and President, who plays a central role in healthcare support, functional-materials development and the construction of a comprehensive healthcare platform, continues to be disclosed.
  2. 2026-08-18ReframedChanges in Directors and Officers

    「Since 角田真佐夫 (角田真佐夫) became representative director and president in September 2024, we have promoted structural reforms and the reorganization of our business portfolio centered on healthcare under the new management structure, while working to build a foundation for medium- to long-term growth.」

    角田真佐夫 (角田真佐夫) is scheduled to be reappointed as representative director and president, continuing the structure established following the previous change in president.
  3. FY2024ReframedAnnual report

    「Tsunoda Masao (角田 真佐夫), the Company's Representative Director and President, joined the Group after working at a biotech company engaged in the sale of medical devices and pharmaceuticals. He launched the healthcare support business, also served as head of the functional-materials development business, which conducts research and development on functional materials covered by numerous patents, and became Representative Director and President in September 2024.」

    The subject of the risk of dependence on the Representative Director and President changed from Ishigami Kentaro (石神 賢太郎) to Tsunoda Masao (角田 真佐夫), who took office in September 2024.
  4. FY2024-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  5. FY2024-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  6. FY2023RestatedAnnual report

    「As this director plays a central role in the overall management and operation of our group's business, if for any reason the director becomes unable to perform duties for the Company, our group's business strategy, operating performance and other matters may be materially affected.」

    The risk of dependence on Ishigami Kentaro (石神 賢太郎), the Representative Director and President, who plays a central role in management and business operations, including business-structure transformation, continues to be disclosed.
  7. FY2023-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  8. FY2023-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  9. FY2022-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  10. FY2021-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  11. FY2021-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  12. FY2020RestatedAnnual report

    「Ishigami Kentaro (石神 賢太郎), the Company's Representative Director and President, joined the Group after working at a domestic management consulting firm and became Representative Director and President in January 2018.」

    The risk of dependence on Ishigami Kentaro (石神 賢太郎), the Representative Director and President, who plays a central role in management and business operations, including business-structure transformation, continues to be disclosed.
  13. FY2020-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  14. FY2020-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk of dependence on the Representative Director and President for management and business operations.
  15. FY2019-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    The risk of dependence on the Representative Director and President for management and business operations is collectively disclosed as having no material changes.
  16. FY2019-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    The risk of dependence on the Representative Director and President for management and business operations is collectively disclosed as having no material changes.
  17. FY2019-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    The risk of dependence on the Representative Director and President for management and business operations is collectively disclosed as having no material changes.
  18. FY2018Dependence changed to President IshigamiAnnual report

    「Ishigami Kentaro (石神 賢太郎), the Company's Representative Director and President, joined our group after working for a domestic management consulting firm and became Representative Director and President in January 2018.」

    The disclosure on dependence on the Representative Director and President for management and business operations changed from Koike Shinya (小池 眞也) to Ishigami Kentaro (石神 賢太郎), who took office in January 2018.
  19. FY2018-Q2Change in Representative Director and PresidentAnnual report

    「Representative Director and President — Koike Shinya (小池 眞也) — 31 January 2018 Representative Director and President; Director — Ishigami Kentaro (石神 賢太郎) — 31 January 2018」

    Koike Shinya (小池 眞也) changed from Representative Director and President, and Ishigami Kentaro (石神 賢太郎) became Representative Director and President on the same day. Although the circumstances surrounding dependence on the former president for management and business operations have changed, no assessment of risk reduction or other effects is disclosed.
  20. FY2016First statedAnnual report

    「As this director plays a central role in the overall management and operation of our group's business, if for any reason the director becomes unable to perform duties for the Company, our group's business strategy, operating performance and other matters may be materially affected.」

    President Koike Shinya (小池 眞也) is stated to play a central role in management and business operations, including transforming the business structure.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Soiken Holdings yet. It last moved in the Changes in Directors and Officers of 2026-08-18: "Reframed".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.